Arches. Photo by Daniel Chia
HOPES: Huntington's Outreach Project for Education, at Stanford
Nov
16
2011

Weight Loss: Demystifying a Medical Mystery

While Huntington’s disease is traditionally thought of as a disease of the brain, its effects are much more widespread: many people with HD lose a dangerous amount of weight, complicating a disease that is already complicated enough. Although weight loss is one of the most serious non-neurological problems of HD, scientists don’t fully understand why [...]

Sep
19
2011

Advance Directives

In the last stages of Huntington’s disease (HD), patients have difficulty thinking and communicating clearly, so decisions about their end-of-life medical care often fall to doctors and relatives. However, many people with HD have strong opinions as to how they would like their last years to unfold. Advance directives are instructions written by mentally and [...]

Sep
13
2011

Antidepressants and HD

P. Bakhai 9.13.11 Print PDF

Aug
23
2011

Stages of Huntington’s Disease

Stages-of-HD People with Huntington’s disease (HD) follow a path of disease progression once symptoms begin. While patients can remain highly functional in the first years of the disease, independence gives way as symptoms get worse. This article discusses the ways in which HD symptoms change from one stage to the next, the degree to which [...]

Jul
30
2011

“Normal” huntingtin and Huntington’s disease

Since the Huntington’s Study Group first identified the mutation responsible for Huntington’s disease (HD) in 1993, there have been many studies conducted seeking to understand how this defective gene causes the drastic neurodegeneration seen in individuals with HD. It is known that the expansion of CAG repeats in the Huntington gene results in a misfolded [...]

Jul
30
2011

University of California at San Francisco 2010 HD Research Symposium

HOPES summary of the talks from scientists and clinicians Note: This article includes references to Dimebon, which is no longer being considered as a potential treatment for HD after the HORIZON clinical trial showed that Dimebon was not better than a placebo. For more information, click here F. Clum, C. Garnett, T. Wang and A, [...]

Jul
26
2011

Genetic Modifiers of Huntington’s Disease

Explaining the variable onset, manifestation, and progression of HD Huntington’s disease (HD) is caused by an expansion in the Huntington gene, which codes for the huntingtin protein. This gene contains a repeated span of three nucleotides, C-A-G, that encode for the amino acid glutamine. Individuals with an increased number of CAG repeats in the HD [...]

Jul
25
2011

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are a type of multipotent stem cell, meaning that they can give rise to many but not all types of cells in the body. MSCs secrete substances, including cytokines and growth factors, that are essential to cell growth and help repair damaged tissue. Researchers are still exploring the functions of human [...]

Jul
20
2011

Family Planning

Family Planning The decision to have a family comes with a great deal of responsibility, and many important choices. For people with Huntington’s disease (HD), one of the most pressing considerations in their decision to have children relates to the disorder. People with HD have a 50% risk of passing the disease to their offspring [...]

Jul
16
2011

Pridopidine (Huntexil, ACR-16)

Drug Summary: Pridopidine, also known as Huntexil or ACR-16, is a dopamine stabilizer intended to improve voluntary movements and reduce chorea. Initial clinical trials – the MermaiHD and HART studies – show promising results, but drug regulation agencies have requested another trial before pridopidine can be sold to the general public. control relevant M. Hedlin, [...]